From NAFLD to MAFLD: a "redefining" moment for fatty liver disease

Kenneth I Zheng¹, Jian-Gao Fan², Jun-Ping Shi³, Vincent Wai-Sun Wong⁴, Mohammed Eslam⁵, Jacob George⁵, Ming-Hua Zheng^{1

6

7}

Affiliations

¹ Department of Hepatology, MAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 25000, China.
² Department of Gastroenterology, Center for Fatty Liver, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai 200065, China.
³ Department of Liver Diseases, Hangzhou Normal University Affiliated Hospital, Hangzhou, Zhejiang 311121, China.
⁴ Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong 999077, China.
⁵ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney 2145, Australia.
⁶ Institute of Hepatology, Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
⁷ Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, Zhejiang 325000, China.

Kenneth I Zheng et al. Chin Med J (Engl). 2020.

. 2020 Oct 5;133(19):2271-2273.

doi: 10.1097/CM9.0000000000000981.

Kenneth I Zheng¹, Jian-Gao Fan², Jun-Ping Shi³, Vincent Wai-Sun Wong⁴, Mohammed Eslam⁵, Jacob George⁵, Ming-Hua Zheng^{1

6

7}

¹ Department of Hepatology, MAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 25000, China.
² Department of Gastroenterology, Center for Fatty Liver, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai 200065, China.
³ Department of Liver Diseases, Hangzhou Normal University Affiliated Hospital, Hangzhou, Zhejiang 311121, China.
⁴ Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong 999077, China.
⁵ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney 2145, Australia.
⁶ Institute of Hepatology, Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
⁷ Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, Zhejiang 325000, China.

No abstract available

Conflict of interest statement

None.

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434–438. - PubMed
1. Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158:1999–2014.e1. doi: 10.1053/j.gastro.2019.11.312. - PubMed
1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67:328–357. doi: 10.1002/hep.29367. - PubMed
1. GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018; 392:1015–1035. doi: 10.1016/s0140-6736(18)31310-2. - PMC - PubMed
1. Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab 2019; 30:675–688.e7. doi: 10.1016/j.cmet.2019.08.018. - PubMed